Organisation paid for research Program year 2023 Source: CMS Open Payments

Womens Obgyn PC

Neither a doctor nor a teaching hospital

Research payments

$662,511

287 payments

Through program year 2023, Womens Obgyn PC is reported as receiving $662,511 in research payments, across 287 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$87,934	24
2022	Research	$353,825	134
2021	Research	$194,209	104
2020	Research	$22,956	24
2019	Research	$3,588	1

Breakdown

Who paid Research payments · program years 2019–2023

GlaxoSmithKline, LLC. $612,429 241 payments
AbbVie, Inc. $46,493 45 payments
Becton, Dickinson and Company $3,588 1 payment

Studies the money was for Research payments · program years 2019–2023

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr $403,165 144 payments
Study name not reported $170,671 83 payments
M14-702 $20,148 19 payments
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain $14,038 20 payments
A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Eva $12,207 2 payments
A Phase Iiib, Open Label, Non-Randomized, Controlled, Multi Country St $12,207 6 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $11,655 5 payments
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain $9,500 1 payment
Viper LT HPV Longitudinal $3,588 1 payment
M16-283 $2,808 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.